Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New

Canadian Journal of Diabetes

Volumn 42, Issue 3, 2018, Pages 325-334

  Goldenberg, Ronald M ^a   Berall, Murray ^b   Chan, Christopher T M ^c,d   Cherney, David Z I ^c,d   Lovshin, Julie A ^e   McFarlane, Philip A ^f   Senior, Peter A ^g   Verma, Subodh ^f   Weinstein, Jordan J ^f  

^a LMC DIABETES AND ENDOCRINOLOGY   (Canada)

^b HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

blood pressure; diabetic kidney disease; DPP 4 inhibitors; GLP 1R agonists; glycemia; SGLT2 inhibitors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; PLACEBO; RENIN INHIBITOR; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MACROALBUMINURIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; RENAL PROTECTION; REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CASE REPORT; FEMALE; GLUCOSE BLOOD LEVEL; MIDDLE AGED;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85027394909     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2017.06.008     Document Type: Review

References (103)

1. Reutens, A.T., Epidemiology of diabetic kidney disease. Med Clin North Am 97 (2013), 1–18.
2. Plantinga, L.C., Crews, D.C., Coresh, J., et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 5 (2010), 673–682.
3. van der Meer, V., Wielders, H.P., Grootendorst, D.C., et al. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. Br J Gen Pract 60 (2010), 884–890.
4. Molitch, M.E., Adler, A.I., Flyvbjerg, A., et al. Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 87 (2015), 20–30.
5. Marshall, S.M., Diabetic nephropathy in type 1 diabetes: Has the outlook improved since the 1980s?. Diabetologia 55 (2012), 2301–2306.
6. Marshall, S.M., Natural history and clinical characteristics of CKD in type 1 and type 2 diabetes mellitus. Adv Chronic Kidney Dis 21 (2014), 267–272.
7. Yu, H.T., Progression of chronic renal failure. Arch Intern Med 163 (2003), 1417–1429.
8. Heilig, C.W., Concepcion, L.A., Riser, B.L., et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 96 (1995), 1802–1814.
9. de Boer, I.H., Rue, T.C., Cleary, P.A., et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 171 (2011), 412–420.
10. Gambara, V., Mecca, G., Remuzzi, G., et al. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol 3 (1993), 1458–1466.
11. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, McFarlane, P., Gilbert, R.E., et al. Chronic kidney disease in diabetes. Can J Diabetes 37:Suppl. 1 (2013), S129–S136.
12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 3 (2013), 1–150.
13. Afkarian, M., Zelnick, L.R., Hall, Y.N., et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA 316 (2016), 602–610.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
15. Nathan, D.M., Bayless, M., Cleary, P., et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Advances and contributions. Diabetes 62 (2013), 3976–3986.
16. DCCT/EDIC Research Group, de Boer, I.H., Sun, W., et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365 (2011), 2366–2376.
17. Stratton, I.M., Adler, A.I., Neil, H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000), 405–412.
18. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
19. ADVANCE Collaborative Group, Patel, A., MacMahon, S., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
20. Zoungas, S., Chalmers, J., Neal, B., et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371 (2014), 1392–1406.
21. Ismail-Beigi, F., Craven, T., Banerji, M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
22. Duckworth, W., Abraira, C., Moritz, T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
23. Coca, S.G., Ismail-Beigi, F., Haq, N., et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172 (2012), 761–769.
24. Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ, 343, 2011, d4169.
25. Gaede, P., Vedel, P., Larsen, N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
26. Gaede, P., Oellgaard, J., Carstensen, B., et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59 (2016), 2298–2307.
27. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Imran, S.A., Rabasa-Lhoret, R., et al. Targets for glycemic control. Can J Diabetes 37:Suppl. 1 (2013), S31–S34.
28. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
29. Handelsman, Y., Bloomgarden, Z.T., Grunberger, G., et al. American Association of Clinical Endocrinologists and American College of Endocrinology: Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan, 2015. Endocr Pract 21:Suppl. 1 (2015), 1–87.
30. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
31. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Booth, G., Lipscombe, L.L., et al. Pharmacologic management of type 2 diabetes: 2016 Interim update. Can J Diabetes 40 (2016), 484–486.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998), 703–713.
33. de Galan, B.E., Perkovic, V., Ninomiya, T., et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 20 (2009), 883–892.
34. Ismail-Beigi, F., Craven, T.E., O'Connor, P.J., et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81 (2012), 586–594.
35. Group, S.R., Wright, J.T. Jr, Williamson, J.D., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
36. Emdin, C.A., Rahimi, K., Neal, B., et al. Blood pressure lowering in type 2 diabetes: A systematic review and meta-analysis. JAMA 313 (2015), 603–615.
37. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001), 870–878.
38. Mann, J.F., Schmieder, R.E., Dyal, L., et al. Effect of telmisartan on renal outcomes: A randomized trial. Ann Intern Med 151 (2009), 1–10.
39. Makino, H., Haneda, M., Babazono, T., et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 (2007), 1577–1578.
40. Hirst, J.A., Taylor, K.S., Stevens, R.J., et al. The impact of renin-angiotensin-aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 81 (2012), 674–683.
41. Brenner, B.M., Cooper, M.E., de Zeeuw, D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001), 861–869.
42. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001), 851–860.
43. Vejakama, P., Thakkinstian, A., Lertrattananon, D., et al. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: A systematic review and network meta-analysis. Diabetologia 55 (2012), 566–578.
44. Bangalore, S., Fakheri, R., Toklu, B., et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: Systematic review and meta-analysis of randomized trials. BMJ, 352, 2016, i438.
45. Leung, A.A., Nerenberg, K., Daskalopoulou, S.S., et al. Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 32 (2016), 569–588.
46. Mann, J.F., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
47. Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
48. Parving, H.H., Brenner, B.M., McMurray, J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
49. Sun, L.J., Sun, Y.N., Shan, J.P., et al. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. J Diabetes Investig 8:4 (2017), 609–618.
50. Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and diabetic kidney disease (FIDELIO-DKD). NCT02540993 https://clinicaltrials.gov/ct2/show/NCT02540993, 2015. (Accessed 14 March 2017)
51. Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease (FIGARO-DKD). NCT02545049 https://clinicaltrials.gov/ct2/show/NCT02545049?term=NCT02545049, 2015. (Accessed 14 March 2017)
52. Lovshin, J.A., GLP-1 receptor agonists: A class update for treating type 2 diabetes. Can J Diabetes, 2017, 10.1016/j.jcjd.2017.02.003 In press.
53. Lovshin, J.A., Drucker, D.J., Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5 (2009), 262–269.
54. Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ Res 114 (2014), 1788–1803.
55. Muskiet, M.H., Smits, M.M., Morsink, L.M., et al. The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes?. Nat Rev Nephrol 10 (2014), 88–103.
56. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
57. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
58. Mann, J.F., Fandsen, K.B., Daniels, G.H., et al. Liraglutide and renal outcomes in type 2 diabetes: Results of the LEADER Trial. Kidney Week, 2016 Abstract# HI-OR01.
59. Gutzwiller, J.P., Tschopp, S., Bock, A., et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89 (2004), 3055–3061.
60. Lovshin, J.A., Barnie, A., DeAlmeida, A., et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 38 (2015), 132–139.
61. Tonneijck, L., Smits, M.M., Muskiet, M.H., et al. Renal Effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39 (2016), 2042–2050.
62. Skov, J., Pedersen, M., Holst, J.J., et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: A randomized clinical trial. Diabetes Obes Metab 18 (2016), 581–589.
63. Sun, F., Wu, S., Guo, S., et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract 110 (2015), 26–37.
64. Rieg, T., Gerasimova, M., Murray, F., et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 303 (2012), F963–F971.
65. Takashima, S., Fujita, H., Fujishima, H., et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int 90 (2016), 783–796.
66. Lovshin, J.A., Rajasekeran, H., Lytvyn, Y., et al. Dipeptidyl peptidase-4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1α1–67 in patients with type 2 diabetes. Diabetes Care, 2017 in press.
67. Shi, S., Srivastava, S.P., Kanasaki, M., et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. Kidney Int 88 (2015), 479–489.
68. Nakashima, S., Matsui, T., Takeuchi, M., et al. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 46 (2014), 717–721.
69. Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA). https://clinicaltrials.gov/ct2/show/NCT01897532?term=CARMELINA, 2013. (Accessed 14 March 2017)
70. Groop, P.H., Cooper, M.E., Perkovic, V., et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 (2013), 3460–3468.
71. Groop, P.H., Cooper, M.E., Perkovic, V., et al. Effects of linagliptin on glycemic control and albuminuria in type 2 diabetes: The MARLINA-T2D Trial. American Diabetes Association 76th Scientific Sessions, 2016 65:17-LB.
72. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
73. Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
74. White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
75. Cornel, J.H., Bakris, G.L., Stevens, S.R., et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS. Diabetes Care 39 (2016), 2304–2310.
76. Mosenzon, O., Leibowitz, G., Bhatt, D.L., et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care 40 (2017), 69–76.
77. Bettge, K., Kahle, M., Abd El Aziz, M.S., et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 19 (2017), 336–347.
78. Perkovic, V., Jardine, M., Vijapurkar, U., et al. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin 31 (2015), 2219–2231.
79. Cefalu, W.T., Leiter, L.A., Yoon, K.H., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52-week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 (2013), 941–950.
80. Heerspink, H.J., Johnsson, E., Gause-Nilsson, I., et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18 (2016), 590–597.
81. Heerspink, H.J., Desai, M., Jardine, M., et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
82. Ridderstråle, M., Andersen, K.R., Toorawa, R., et al. Empagliflozin (EMPA) compared with glimepiride (GLIM) as add-on to metformin (MET) for 4 years in patients with type 2 diabetes (T2DM). Diabetes, 61, 2016 A47 (184-OR).
83. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
84. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 2017 in press.
85. Thomas, M.C., Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 5 (2014), 53–61.
86. Skrtic, M., Cherney, D.Z., Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24 (2015), 96–103.
87. Lytvyn, Y., Skrtic, M., Yang, G.K., et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308 (2015), F77–F83.
88. Vasilakou, D., Karagiannis, T., Athanasiadou, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
89. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
90. Sano, M., Takei, M., Shiraishi, Y., et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
91. Gilbert, R.E., SGLT2 inhibitors: Beta blockers for the kidney?. Lancet Diabetes Endocrinol, 4, 2016, 814.
92. Ferrannini, E., Mark, M., Mayoux, E., CV Protection in the EMPA-REG OUTCOME trial: A “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
93. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
94. Cherney, D., Lund, S.S., Perkins, B.A., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59 (2016), 1860–1870.
95. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15 (2013), 463–473.
96. Fioretto, P., Stefansson, B.V., Johnsson, E., et al. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59 (2016), 2036–2039.
97. Steen, O., Goldenberg, R.M., The role of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Can J Diabetes, 2017 in press.
98. Collins, A.J., Foley, R.N., Chavers, B., et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis 59:A7 (2012), e1–420.
99. United States Renal Data System, USRDS annual data report: Epidemiology of kidney disease in the United States. 2016, National Institutes of Health, Bethesda (MD), 2016.
100. Perkovic, V., Agarwal, R., Fioretto, P., et al. Management of patients with diabetes and CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies conference. Kidney Int 90 (2016), 1175–1183.
101. Wheeler, D.C., Becker, G.J., Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. Kidney Int 83 (2013), 377–383.
102. Wheeler, D.C., Kasiske, B.L., Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study. Kidney Int 89 (2016), 1189–1191.
103. Marso, S.P., Mann, J.F., Buse, J.B., et al. Results of the liraglutide effect and action in diabetes—evaluation of cardiovascular outcome results (LEADER) trial. 2016, American Diabetes Association Session 3-CT-SY24.